The oncological significance of the VEGF molecule is evident from the established use bevacizumab (Avastin), a humanised anti-VEGF monoclonal antibody in the treatment of metastatic breast, colorectal, renal and non-small cell lung carcinoma (Goerner et al, 2010). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.